Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 448, 637 (9 August 2007) | doi:10.1038/448637a; Published online 8 August 2007
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Manager Medical Writitng
- Indegene Lifesystems Pvt. Ltd
- Bengaluru 560 071 India
Natural Products Chemist
- Praj Matrix - Praj Industries Ltd
- Pune, Maharashtra Pune-411021 India
In brief
An advisory panel to the US Food and Drug Administration (FDA) has said that the diabetes drug Avandia (rosiglitazone) raises the risk of heart attack, but recommended against pulling it from the market, on a vote of 22 to 1. The drug, which generated £1.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
